Unlocking AI’s Potential in Medicine

SESSION SPOTLIGHT

Artificial intelligence continues to transform life sciences with breathtaking speed. With the application of computation in health care comes trailblazing scientific discoveries, earlier cancer detection, personalized oncology therapies and better patient outcomes.

Join us virtually on March 29th at 11am ET for an insightful conversation about the most promising investment opportunities and commercial applications at the intersection of AI, health care and precision medicine.

ADDITIONAL SPEAKERS

DR. NWORAH AYOGU

Amazon Clinic

KARIN CONDE-KNAPE

Novo Nordisk A/S

LARS FRUERGAARD JØRGENSEN

Novo Nordisk A/S

STEPHEN SQUINTO

J.P. Morgan Life Sciences

EMMA WALMSLEY

GSK

Stay tuned for additional speaker announcements.

Think a friend or colleague should receive this invitation? Please feel free to share the registration link above.

Terms of Service | Privacy Policy | CNBC Events Policy | Unsubscribe

© 2023 CNBC LLC. All rights reserved. A property of NBCUniversal Media, LLC
1 CNBC Plaza, 900 Sylvan Avenue, Englewood Cliffs, NJ 07632

Comments

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition. In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates. So, why is this approval so important? First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with...

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly? The answer isn't clear yet. We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct. But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – c...

MediaCenter Panda Security

MediaCenter Panda Security Do you use uTorrent? Careful with what it installs in your computer! Posted: 30 Mar 2015 06:53 AM PDT If you love downloading things of the Internet , probably you know uTorrent , one of the most famous clients of BitTorrent , which allows us to download files quickly and free. In spite of the annoying banners that constantly accost users. There are many webs where you can check how to eliminate these sponsored advertisements. Nevertheless, Bit Torrent, with 150 millions of users per month, suffered strong reviews in the last few days because of their latest update design. As one user explained in the uTorrent forums, they had installed new software, without warning him. He only realized it when he saw that his processor was consuming more resources than it should. In this particular case, the program that sneaked into his computer was EpicScale, a mining bitcoins software. To those who don't know how the...

DBTECH

Search This Blog